AXON
Price
$527.76
Change
+$2.46 (+0.47%)
Updated
Jul 31 closing price
Capitalization
42.54B
2 days until earnings call
Intraday BUY SELL Signals
DNA
Price
$8.09
Change
-$0.00 (-0.00%)
Updated
Jul 31 closing price
Capitalization
528.48M
3 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AXON vs DNA

AXON vs DNA Comparison Chart in %
View a ticker or compare two or three
VS
AXON vs. DNA commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Hold and DNA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 03, 2026
Stock price -- (AXON: $527.76 vs. DNA: $8.09)
Brand notoriety: AXON and DNA are both not notable
AXON represents the Aerospace & Defense, while DNA is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: AXON: 31% vs. DNA: 55%
Market capitalization -- AXON: $42.54B vs. DNA: $528.48M
AXON [@Aerospace & Defense] is valued at $42.54B. DNA’s [@Biotechnology] market capitalization is $528.48M. The market cap for tickers in the [@Aerospace & Defense] industry ranges from $1.43T to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $121.09B to $0. The average market capitalization across the [@Aerospace & Defense] industry is $37.21B. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AXON’s FA Score shows that 1 FA rating(s) are green whileDNA’s FA Score has 1 green FA rating(s).

  • AXON’s FA Score: 1 green, 4 red.
  • DNA’s FA Score: 1 green, 4 red.
According to our system of comparison, AXON is a better buy in the long-term than DNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AXON’s TA Score shows that 4 TA indicator(s) are bullish while DNA’s TA Score has 5 bullish TA indicator(s).

  • AXON’s TA Score: 4 bullish, 4 bearish.
  • DNA’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both AXON and DNA are a good buy in the short-term.

Price Growth

AXON (@Aerospace & Defense) experienced а +5.06% price change this week, while DNA (@Biotechnology) price change was +9.92% for the same time period.

The average weekly price growth across all stocks in the @Aerospace & Defense industry was +5.98%. For the same industry, the average monthly price growth was -12.27%, and the average quarterly price growth was -7.58%.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.22%. For the same industry, the average monthly price growth was -8.12%, and the average quarterly price growth was +2790.29%.

Reported Earning Dates

AXON is expected to report earnings on Aug 05, 2026.

DNA is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Aerospace & Defense (+5.98% weekly)

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

@Biotechnology (-1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AXON($42.5B) has a higher market cap than DNA($528M). DNA YTD gains are higher at: -2.647 vs. AXON (-7.073). AXON has higher annual earnings (EBITDA): 320M vs. DNA (-251.5M). AXON has more cash in the bank: 737M vs. DNA (373M). DNA has less debt than AXON: DNA (411M) vs AXON (1.83B). AXON has higher revenues than DNA: AXON (2.98B) vs DNA (151M).
AXONDNAAXON / DNA
Capitalization42.5B528M8,049%
EBITDA320M-251.5M-127%
Gain YTD-7.073-2.647267%
P/E Ratio212.81N/A-
Revenue2.98B151M1,975%
Total Cash737M373M198%
Total Debt1.83B411M445%
FUNDAMENTALS RATINGS
AXON: Fundamental Ratings
AXON
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
PROFIT vs RISK RATING
1..100
62
SMR RATING
1..100
82
PRICE GROWTH RATING
1..100
52
P/E GROWTH RATING
1..100
33
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AXONDNA
RSI
ODDS (%)
Bearish Trend 3 days ago
61%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
86%
Momentum
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
72%
Bearish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
71%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 6 days ago
74%
Bullish Trend 6 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
70%
Bearish Trend 14 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
61%
Bullish Trend 3 days ago
85%
Aroon
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
AXON
Daily Signal:
Gain/Loss:
DNA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FNICX33.570.39
+1.18%
Fidelity Advisor New Insights C
GSXIX54.11-0.02
-0.04%
abrdn US Small Cap Equity Inst Svc
MXMVX16.57-0.04
-0.24%
Empower Mid Cap Value Inv
DPRCX14.71-0.08
-0.54%
Nomura Global Listed Real Assets C
OGMCX45.86-1.41
-2.98%
Invesco Gold & Special Minerals C

DNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNA has been loosely correlated with VCYT. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNA
1D Price
Change %
DNA100%
N/A
VCYT - DNA
58%
Loosely correlated
-22.52%
RXRX - DNA
51%
Loosely correlated
-1.32%
ABCL - DNA
51%
Loosely correlated
+0.35%
ABSI - DNA
44%
Loosely correlated
+1.83%
AXON - DNA
44%
Loosely correlated
+0.47%
More